Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

A medical probe under development at NASA promises to identify cancerous tumors without requiring surgical biopsies. San Jose, CA-based BioLuminate recently obtained a license from NASA to produce a disposable needle that makes real-time measurements of breast tissue to distinguish potentially cancerous masses. Sensors in the tip of the instrument register data such as tissue density, oxygen levels and density of blood vessels. The probe has the potential to significantly reduce the more than 16,000 unnecessary surgical breast biopsies performed weekly in the United States. The smart needle should be available for breast cancer detection in about three years. From there, the technology may be applied to identify prostate, colon, cervical and brain tumors.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me